
Dental pulp tissue engineering requires preservation of dental pulp stem cell (DPSCs) function under adverse conditions while supporting differentiation and tissue formation. Pulsed electromagnetic fields (PEMFs) are non-invasive modulators of cellular function, but their effects on DPSCs cytoprotection under oxidative challenge and on odontoblastic differentiation and pulp-like tissue formation remain unclear. Here, direct PEMF exposure preserved metabolic activity and cytoskeletal organization and reduced intracellular reactive oxygen species (ROS) under moderate oxidative stress while PEMF-conditioned medium preserved membrane integrity, and both accelerated wound closure. PEMF exposure increased intracellular calcium above a time-dependent rise common to exposed and unexposed cells, and this increase was no longer discernible after inhibition of transient receptor potential canonical (TRPC) channels 1, 4 and 5, supporting a TRPC-associated response to the field. PEMF-conditioned medium increased odontogenic marker expression and mineralization in vitro, while transcriptomic analysis identified early changes involving mitochondrial and biosynthetic processes. In a cell-seeded tooth-slice model, cells preconditioned with PEMF-conditioned medium supported the formation of a pulp-like tissue with a collagenous matrix and showed higher vessel density than controls (no PEMF). Collectively, these findings show that PEMF supports DPSCs resilience under oxidative challenge and regenerative functions relevant to pulp tissue formation across complementary experimental models, with potential implications for dental pulp tissue engineering.
Cardiovascular disease causes substantial mortality. Following myocardial infarction (MI), limited adult myocardial regeneration contributes to adverse ventricular remodeling and heart failure. Ischemic injury causes irreversible cardiomyocyte loss, activates inflammatory pathways including nuclear factor kappa B (NF-κB) and mitogen-activated protein kinase (MAPK) signaling, and increases matrix metalloproteinase (MMP) activity, promoting extracellular matrix remodeling, scar formation, and functional decline. Current therapies improve survival and limit disease progression but do not restore vascularized, mechanically compliant, electrically integrated myocardium. This review critically evaluates electroactive hydrogels for MI repair, focusing on poly(ethylene glycol) (PEG)/poly(ε-caprolactone) (PCL) scaffolds, MXenes, ginseng-derived bioactives, and three-dimensional (3D) bioprinting. PEG/PCL scaffolds offer tunable mechanics, degradation, injectability, and printability; MXenes provide conductive, hydrophilic, hydrogel-compatible interfaces. Long-term MXene performance depends on preserved conductivity in the oxidative and inflammatory post-infarction microenvironment. MXenes are compared with graphene derivatives, carbon nanotubes, metallic nanostructures, and conductive polymers for performance and translation. Ginseng-derived bioactives are examined as potential modulators of oxidative, inflammatory, vascular, and fibrotic processes, emphasizing standardization, controlled release, potency, and multicomponent interactions. 3D bioprinting spatially controls scaffold architecture and localized cue delivery, although structural organization alone does not establish therapeutic efficacy. Together, these technologies define an evidence-informed preclinical cardiac scaffold framework, while integrated-platform efficacy remains unproven. Clinical translation requires comparative validation, long-term in vivo safety assessment, large-animal studies, scalable, reproducible manufacturing, sterilization compatibility, robust quality control, and regulatory strategy.
Radiotherapy remains underutilized in colon cancer despite the intrinsic radiosensitivity of colon cancer cells, largely because accurate targeting of tumors within the highly mobile colon is technically challenging. Tumor motion caused by peristalsis, bowel motility, and respiration limits the precision of radiation delivery and increases the risk of damage to surrounding radiosensitive tissues. Current endoscopic tattooing agents used for tumor localization are used for operative localization only and lack radiographic visibility, may diffuse from the injection site, and can induce local inflammation.Here, we developed a thermo-responsive, CT-detectable, injectable fiducial marker composed of Poly(N-isopropylacrylamide) (PNIPAM) loaded with barium sulfate (BaSO₄) for potential application in tumor localization during image-guided radiotherapy. The PNIPAM-BaSO₄ formulation remained injectable at room temperature and rapidly underwent in situ gelation within approximately 15 s at physiological temperature. Micro-CT imaging demonstrated strong dose-dependent radiopacity both in vitro and in vivo, supporting the potential of the marker for CT-based visualization. The marker exhibited stable mass retention for up to 280 days in vitro, and maintained stable localization and radiographic signal for 3 months in vivo without detectable diffusion. Histopathological analysis revealed no evidence of local inflammation, fibrosis, necrosis, or systemic toxicity, demonstrating excellent biocompatibility.Collectively, these findings establish the feasibility of the PNIPAM-BaSO₄ platform as a stable, CT-detectable fiducial marker and support its further development for potential application in image-guided radiotherapy. Future studies will evaluate its performance under clinically relevant radiotherapy imaging and treatment conditions, including its potential use for interfractional localization of mobile tumors.
Deciphering the regulation of localized proteolytic activity of cancer cells requires convenient and robust readouts of proteolytic activity. Toward this end, this paper describes a printed fibrin microstructure degradation analysis workflow with time lapse imaging based, parallelized measurement of pericellular fibrin degradation. This workflow is applied to two types of breast cancer cells and a normal mammary epithelial cell line. The baseline pericellular fibrin degradation activity as well as response upon exposure to bacteria-derived lipopolysaccharide (LPS), varies significantly between these cell types. Recombinant plasminogen activator inhibitor 1 (PAI1), which inhibits production of the main fibrinolytic protease plasmin, dose dependently inhibits fibrin degradation by the two breast cancer cell lines but has only a small effect on the normal epithelial cell line consistent with reports that normal cells generally have lower plasminogen activator expression than cancer cells. Interestingly, all the epithelial cell lines degrade the fibrin microstructures in a minimal media that excludes the plasminogen containing serum, suggesting sensitivity of this assay to the activity of fibrin-degrading enzymes other than plasmin. This workflow of determining plasmin and non-plasmin mediated as well as cell context dependent pericellular fibrin degrading activity, when applied to a previously reported endothelial fibrin degradation assay reconfirms the highly plasmin dependent nature of endothelial cell fibrin degradation while newly revealing significant fibrin degradation enhancing effects of VEGF and FGF. This expanded and updated fibrin microstructure degradation assay workflow clearly visualizes previously underappreciated cell type and cell context dependence of pericellular fibrin degrading activity with implications for breast cancer studies and beyond.